OccuLogix, Inc.

OccuLogix, Inc.

November 17, 2005 08:30 ET

All 12-Month Follow-up Visits Completed in OccuLogix's Pivotal Trial for Dry Age-Related Macular Degeneration

TORONTO, ONTARIO--(CCNMatthews - Nov. 17, 2005) - OccuLogix, Inc. (NASDAQ:RHEO)(TSX:RHE) today announced that all final study visits have been completed for the pivotal (phase III) MIRA-1 Trial.

In December 2004, OccuLogix completed enrollment for participation in MIRA-1, or Multicenter Investigation of Rheopheresis for AMD, its pivotal stage clinical trial using its RHEO™ System to treat the dry form of age-related macular degeneration ("Dry AMD"). MIRA-1 is a multi-center, randomized (2:1), double-masked and placebo-controlled trial designed to evaluate the safety and efficacy of RHEO™ Therapy in patients with intermediate-to-late stage, or Category 3 and Category 4, Dry AMD. If successful, MIRA-1 is expected to support OccuLogix's application to the U.S. Food and Drug Administration ("FDA") for approval to market its RHEO™ System in the United States.

Elias Vamvakas, OccuLogix's Chairman and CEO, commented "A total of 169 subjects in MIRA-1 completed their 12-month follow-up exams, exceeding the Company's goal of achieving at least 150 complete data sets. This marks yet another important milestone achieved by OccuLogix on, or in this case ahead of, schedule."

Vamvakas continued, "No one at the Company, or at the MIRA-1 trial sites, will know what the raw data is, or have a chance to analyze it, until our contract research organization, Promedica International, has completed the work it needs to do before the database is hard-locked. That process will take several weeks to complete. Therefore, I caution investors not to put any weight in the rumor and speculation - pro or con - that often surrounds an event like this. We will, of course, let everyone know the trial results as soon as we possibly can. We expect that to happen before the end of Q1-06."

About OccuLogix, Inc.

OccuLogix is a health care company that brings innovative and evidenced-based medical therapies to market. OccuLogix's common shares trade on the NASDAQ National Market under the symbol 'RHEO' and on the Toronto Stock Exchange under the symbol 'RHE'. Visit us on the internet at www.occulogix.com (corporate) and www.rheo.com (healthcare professionals, patients and caregivers).

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about the company. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian regulatory authorities, including our Registration Statement on Form S-1. We do not undertake to update any forward-looking statements.

Contact Information